Analytical performance of HPV assays on vaginal self -collected vs practitioner -collected cervical samples: the SCoPE study
M Saville, D Hawkes, MHT Keung, ELO Ip, J Silvers, F Sultana, MJ Malloy, LS Velentzis, K Canfel, CD Wrede, JML Brotherton
Journal of Clinical Virology | ELSEVIER | Published : 2020
BACKGROUND: In the last decade, human papillomavirus (HPV) testing has been evaluated extensively for cervical screening, with studies finding increased sensitivity compared to cytology. Another advantage of HPV based-screening is the ability to test vaginal samples that can be collected by women themselves. Self-collection has the potential to extend cervical screening coverage by increasing participation rates, particularly among women who are under-screened or have never screened. This could have a significant impact on cervical cancer prevention, as the majority of invasive cervical cancer cases occur among under-screened women. Both the Netherlands and Australia have transitioned their ..View full abstract
The test kits for this study were supplied free of charge from Abbott, BD, Roche, Seegene and Cepheid. None of the manufacturers had any influence on the study design, analysis or production of this manuscript. KC is a co-PI of an investigator-initiated trial of cervical cytology and primary HPV screening in Australia ('Compass'), which is conducted and funded by the VCS foundation, a government-funded health promotion charity. DH, MS, JMLB, ELOI, MHTK, MM, FS were employed by VCS Foundation. The VCS foundation have received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and Ventana Inc USA. However neither I nor my institution on my behalf (Cancer Council NSW) receives direct funding from industry for this trial or any other project. DH has received travel funding to attend conferences and meetings from Roche, Abbott and Seegene but has had no personal gain from any diagnostics manufacturer.